• Papadopoulos, K. P., Borazanci, E., Shaw, A. T., katayama, R., Shimizu, Y., Zhu, V. W., sun, T. Y., Wakelee, H. A., Madison, R., Schrock, A. B., Senaldi, G., Nakao, N., Hanzawa, H., Tachibana, M., Isoyama, T., Nakamaru, K., Deng, C., Li, M., Fran, F., Zhao, O., Gao, Y., Seto, T., Janne, P. A. and Ou, S. H. I.
  US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors.
  Clin. Cancer Res., in press (2020)
• Arai, S., Takeuchi, S., Fukuda, K., Taniguchi, H., Nishiyama, A., Tanimoto, A., Satouchi, M., Yamashita, K., Ohtsubo, K., Nanjo, S., Kumagai, T., Katayama, R., Nishio, M., Zheng, M. M., Wu, Y. L., Nishihara, H., Yamamoto, T., Nakada, M. and Yano, S.
  Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer.
  J. Thorac. Oncol., 15, 752-765 (2020)
• Ono, F., Chiba, S., Isaka, Y., Matsumoto, S., Ma, B., Katayama, R., Araki, M. and Okuno, Y.
  Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method.
  Sci. Rep., 10, 2161 (2020)
• Yanagitani, N., Uchibori, K., Koike, S., Tsukahara, M., Kitazono, S., Yoshizawa, T., Horiike, A., Ohyanagi, F., Tambo, Y., Nishikawa, S., Fujita, N., Katayama, R. and Nishio, M.
  Drug resistance mechanisms in Japanese ALK positive NSCLC and the clinical responses based on the resistant mechanisms.
  Cancer Sci., 111, 932-939 (2020)
• Fujimura, A., Hayashi, Y., Kato, K., Kogure, Y., Kameyama, M., Shimamoto, H., Daitoku, H., Fukamizu, A., Hirota, T. and Kimura, K.
  Identification of a novel nucleolar protein complex required for mitotic chromosome segregation through centromeric accumulation of Aurora B.
  Nucleic Acids Res., in press (2020)

more